Tagged with B

Turkey Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both markets with a track record of six decades. In addition, Drechsel explains how the German company has moved from fifth…

Saudi Arabia Mohamed Fawzy highlights how Pfizer’s work in Saudi Arabia dovetails with the country’s ambitious ‘Vision 2030’ transformation strategy, the Saudi market’s increasing relevance to the company, and how Pfizer is working for the benefit of the Saudi people on COVID-19 vaccine access and beyond.   In simple terms, Vision 2030…

Switzerland Mental health is a global crisis. 25 percent of the world’s population struggle with mental illness; and mental, neurological, and substance use disorders account for 11 percent of the total global disease burden according to data from the Healthy Brains Global Initiative (HBGI). Global mental healthcare costs are expected to…

Switzerland A. Vogel CEO Dr Andy Suter outlines the Swiss herbal medicine market leader’s expansion in recent years, why it is prioritising R&D more than ever, and how the COVID-19 pandemic has created a renewed focus on phytopharmaceuticals and preventive medicine.   There is a segment of people looking to take…

Turkey The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for…

Brazil The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine in Brazil; and how domestic champion EMS surged in performance in 2020 thanks to COVID.   Brazil probes Health Ministry…

Saudi Arabia Ashraf Daoud, General Manager for AbbVie in Saudi Arabia, highlights how the affiliate has harnessed Allergan’s portfolio to become a top five company in the market with the objective of becoming the biopharma leader by 2022. In addition, Daoud discusses the impact that an internal Saudization strategy has had, the…

Indonesia With a market value of USD 5.2 billion, Kalbe Farma has consolidated into Indonesia’s undisputed national pharma champion and has established a footprint in many ASEAN countries as well as in Africa. Today, the largest publicly listed pharmaceutical company in Southeast Asia is aiming to seize on their COVID-19-related partnership…

China Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation with Sanofi China’s Irene Deng, looks at how Chinese pharmaceutical regulations have evolved and what impact this has had on regulatory professionals in the country.   The Chinese pharmaceutical industry, through the first five…

Mexico The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout of the J&J jab, why the country’s doctors are being denied vaccines, and the progression of trials for the Sanofi…

USA Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might evolve post-COVID.   AAM and our member companies have experienced a year like no other, and the lessons of the…

Saudi Arabia Lilly Saudi Arabia’s Dimitri Livadas shares some of the misconceptions he had before moving to the Kingdom a couple of years ago, highlights the evolution of the Saudi healthcare system with its current focus on digital health, the big opportunities for the Indiana-based company’s diabetes portfolio at a moment when…